Korro Bio (KRRO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	131.59 mm	131.59 mm	131.59 mm	131.59 mm	131.59 mm	131.59 mm
Cash burn (monthly)	18.63 mm	(no burn)	7.76 mm	7.98 mm	5.37 mm	6.14 mm
Cash used (since last report)	94.67 mm	n/a	39.45 mm	40.55 mm	27.26 mm	31.20 mm
Cash remaining	36.92 mm	n/a	92.13 mm	91.03 mm	104.32 mm	100.38 mm
Runway (months of cash)	2.0	n/a	11.9	11.4	19.4	16.3

Beta Read what these cash burn values mean

Financial data from Korro Bio earnings reports.

Institutional ownership, Q3 2024

KRRO institutional ownership history Ownership history

83.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	51	67	-23.9%
Opened positions	12	27	-55.6%
Closed positions	28	11	+154.5%
Increased positions	13	16	-18.8%
Reduced positions	9	12	-25.0%

13F shares	Current	Prev Q	Change
Total value	159.05 bn	282.70 bn	-43.7%
Total shares	7.79 mm	11.43 mm	-31.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Atlas Venture Life Science Advisors	1.14 mm	$38.00 bn	0.0%
New Enterprise Associates 17	1.09 mm	$74.59 mm	0.0%
Atlas Venture Fund XI	942.08 k	$282.00 k	0.0%
Deep Track Capital	850.00 k	$28.41 bn	+10.3%
FMR	579.56 k	$19.37 bn	-9.3%
Platanus Investment	540.17 k	$162.00 k	0.0%
BlackRock	449.95 k	$15.04 bn	NEW
Vanguard	436.86 k	$14.60 bn	-6.7%
Siren, L.L.C.	418.83 k	$14.00 bn	NEW
Artal International S.C.A.	413.07 k	$0.00	-1.3%

Largest transactions	Shares	Bought/sold	Change
NEA Management	0.00	-1.09 mm	EXIT
Citadel Advisors	0.00	-529.17 k	EXIT
Eventide Asset Managment	0.00	-529.16 k	EXIT
Point72 Asset Management	0.00	-456.09 k	EXIT
BlackRock	449.95 k	+449.95 k	NEW
Siren, L.L.C.	418.83 k	+418.83 k	NEW
Artal	0.00	-413.07 k	EXIT
BLK BlackRock	0.00	-406.38 k	EXIT
72 Investment	0.00	-276.83 k	EXIT
Cormorant Asset Management	0.00	-265.83 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KRRO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Feb 25	Olukemi Olugemo	Stock Option Common Stock	Grant	Acquire A	No	No	33.5	42,000	1.41 mm	42,000
3 Feb 25	Ram Aiyar	Stock Option Common Stock	Grant	Acquire A	No	No	33.5	100,000	3.35 mm	100,000
3 Feb 25	Todd Chappell	Stock Option Common Stock	Grant	Acquire A	No	No	33.5	34,500	1.16 mm	34,500
3 Feb 25	Jeffrey Cerio	Stock Option Common Stock	Grant	Acquire A	No	No	33.5	29,000	971.50 k	29,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Korro Announces Initiation Of Dosing In REWRITE Study For KRRO-110 Using OPERATM Platform; Interim Results Expected H2 2025; Plans To Advance Additional Pipeline Program

13 Jan 25

KRRO-110 is the first product candidate from Korro's proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025Korro to advance additional pipeline programs towards clinical

Press releases

From Benzinga Pro

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

13 Jan 25

KRRO-110 is the first product candidate from Korro's proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline programs towards clinical